标题
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
作者
关键词
-
出版物
BLOOD
Volume 139, Issue 18, Pages 2737-2746
出版商
American Society of Hematology
发表日期
2022-03-04
DOI
10.1182/blood.2022015789
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
- (2021) Paolo F Caimi et al. LANCET ONCOLOGY
- Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
- (2021) Gloria Iacoboni et al. Cancer Medicine
- WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING
- (2021) L. K Hilton et al. HEMATOLOGICAL ONCOLOGY
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
- (2021) Stephen J Schuster et al. LANCET ONCOLOGY
- Treatment resistance in diffuse large B-cell lymphoma
- (2021) Michael Y. He et al. LEUKEMIA
- Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)
- (2021) Sattva S. Neelapu et al. BLOOD
- Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology
- (2021) Henry S. Ngu et al. BLOOD
- Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
- (2021) Jeremy S. Abramson et al. BLOOD
- Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
- (2021) Jeremy S. Abramson et al. BLOOD
- Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
- (2021) Caron Jacobson et al. BLOOD
- Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
- (2021) Daniel J Landsburg et al. BLOOD
- Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
- (2021) Mahmoud Elsawy et al. BLOOD
- Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction
- (2021) Frederick L. Locke et al. BLOOD
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- (2021) Michael R. Bishop et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
- (2020) Michael D. Jain et al. BLOOD
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
- (2020) Alison R. Sehgal et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
- (2020) Nagesh Kalakonda et al. Lancet Haematology
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
- (2020) Kitsada Wudhikarn et al. Blood Advances
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2019) Yucai Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2018) John Heymach et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
- (2017) Gustaaf W. van Imhoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2014) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now